Objective：To investigate the serum level of stanniocalcin-1（STC1） in patients with stable chronic obstructive pulmonary diseases（COPD） and to explore the relationship between STC1 and severity of the disease. Method：A total of 55 patients with definite stable COPD and 24 healthy controls were enrolled in this study. Serum STC1 was measured by enzyme-linked immunosorbent assay（ELISA），and the correlation between STC1 and COPD was analyzed. Results：①Serum STC1 levels were significantly lower in patients with COPD than healthy controls（P < 0.05）. ②The receiver-operating characteristic（ROC） curve of serum SCT1 was used for threshold identification（AUC=0.659，P=0.025），the optimal cut-off point of serum STC1 was 1 350 pg/mL（sensitivity 81.82%，specificity 50.00%，respectively）. ③Poor association of serum STC1 levels with stable COPD was found，including the GOLD classification，COPD assessment test（CAT） scores and lung functions. Conclusion：Serum STC1 levels were significantly decreased in COPD patients while it is poorly correlated with disease severity. STC1 might have clinical application in stable COPD.